Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.52 |
| ▸ | USP14 | P54578 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725664 | 1.00 | CCR2 (0.55) | CCR2DRD2DRD4TEAD1USP14 | |
| SCHEMBL29725714 | 1.00 | CCR2 (0.55) | CCR2DRD2DRD4TEAD1USP14 | |
| SCHEMBL4848198 | 0.93 | KMT2A (0.60) | CCR2KMT2AL3MBTL1 | |
| SCHEMBL26502013 | 0.93 | KMT2A (0.60) | CCR2KMT2AL3MBTL1 | |
| SCHEMBL3993415 | 0.91 | SIGMAR1 (0.51) | CCR2DRD2DRD4TEAD1SIGMAR1 | |
| SCHEMBL458295 | 0.91 | SIGMAR1 (0.51) | CCR2DRD2DRD4TEAD1SIGMAR1 | |
| SCHEMBL23152284 | 0.89 | KMT2A (0.49) | CCR2DRD2DRD4TEAD1KMT2A | |
| SCHEMBL4231721 | 0.89 | DRD2 (0.55) | CCR2DRD2DRD4TEAD1SIGMAR1 | |
| SCHEMBL2030049 | 0.89 | DRD2 (0.55) | CCR2DRD2DRD4TEAD1SIGMAR1 | |
| SCHEMBL28674382 | 0.89 | KMT2A (0.49) | CCR2DRD2DRD4TEAD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590088-B2 | Jak inhibitor compound and pharmaceutical composition including the same | KOREA PHARMA CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20220220109-A1 | JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOREA PHARMA CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7390830-B1 | Remedies or prophylactics for diseases in association with chemokines | TEIJIN LIMITED (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20070249701-A1 | Cyclic amine CCR5 receptor antagonists | TEIJIN LIMITED | 2007-10-25 | — | — | US | disclosed |
| EP-1238970-B9 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | TEIJIN PHARMA LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1238970-B1 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1179341-B1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LTD (JP) | 2005-11-09 | — | — | EP | disclosed |
| EP-1553085-A1 | Cyclic amine derivatives and their use as drugs | TEIJIN LIMITED (JP) | 2005-07-13 | — | — | EP | disclosed |
| CN-1433402-A | Cycloamine CCR5 receptor antagonists | TEIJIN LTD (JP) | 2003-07-30 | — | — | CN | disclosed |
| CN-1384743-A | Remedies or preventives for diseases in association with chemokines | TEIJIN LTD (JP) | 2002-12-11 | — | — | CN | disclosed |
| CN-1376063-A | Cyclic amine CCR3 antagonisis | TEIJIN LTD (JP) | 2002-10-23 | — | — | CN | disclosed |
| US-6451842-B1 | Cyclic amine derivatives and their use as drugs | DUPONT PHARMACEUTICALS COMPANY | 2002-09-17 | — | — | US | disclosed |
| EP-1238970-A1 | CYCLOAMINE CCR5 RECEPTOR ANTAGONISTS | TEIJIN LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6410566-B1 | ATHEROSCLEROSIS; ANTIARTHRITIC AGENTS | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1201239-A1 | CYCLIC AMINE CCR3 ANTAGONISTS | TEIJIN LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-6362177-B1 | INHIBITION OF CHEMOKINE BINDING | TEIJIN LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1179341-A1 | REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES | TEIJIN LIMITED (JP) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069815-A1 | UREIDO-SUBSTITUTED CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUG | TEIJIN LIMITED (JP) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010509-A1 | Cycloamine ccr5 receptor antagonists | CCR5, CCR2, CCR1 | CCR2 2/4885DRD2 522/4885DRD4 1018/4885 |
| US-20220220109-A1 | JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | JAK1, JAK2, JAK3 | CCR2 833/4885DRD2 3782/4885DRD4 4341/4885 |
| US-12590088-B2 | Jak inhibitor compound and pharmaceutical composition including the same | JAK1, JAK2, JAK3 | CCR2 450/4885DRD2 1971/4885DRD4 2585/4885 |
| US-20070249701-A1 | Cyclic amine CCR5 receptor antagonists | CCR5, CCR7, CCR2 | CCR2 3/4885DRD2 719/4885DRD4 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.